Ascendis Pharma A/S (ASND) Q2 2024 Earnings Conference Call September 3, 2024 4:30 PM ET

Company Participants

Tim Lee - Senior Director, Investor Relations
Jan Moller Mikkelsen - President & Chief Executive Officer
Scott Smith - Executive Vice President & Chief Financial Officer
Camilla Harder Hartvig - Head of Global Commercial Operation
Joe Kelly - US General Manager

Conference Call Participants

Jessica Fye - JPMorgan
Tazeen Ahmad - Bank of America
Derek Archila - Wells Fargo
Li Watsek - Cantor
Gavin Clark-Gartner - Evercore ISI
Vikram Purohit - Morgan Stanley
Kelly Shi - Jefferies
David Lebowitz - Citi
Alex Thompson - Stifel
Paul Choi - Goldman Sachs
Yaron Werber - TD Cowen

Operator

Hello. Thank you for standing by. Welcome to Ascendis Pharma's Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator instructions]

I would now like to turn the call over to Tim Lee, Senior Director of Investor Relations at Ascendis Pharma. Sir, you may begin.

Tim Lee

Thank you, operator, and thank you, everyone, for joining our second quarter 2024 financial results conference call. We apologize for the delay due to some technical issues that we had here. I'm Tim Lee, Senior Director, Investor Relations at Ascendis Pharma. Joining me on the call today are Jan Mikkelsen, President and Chief Executive Officer; Scott Smith, Executive Vice President and Chief Financial Officer; Dr. Stina Singel, Executive Vice President and Head of Clinical Development Oncology; Camilla Harder Hartvig, Executive Vice President and Global Chief Commercial Officer; and Joe Kelly, US General Manager.

Before we begin, I'd like to remind you that this conference call will contain forward-looking statements that are intended to be covered under safe harbor provided by the Private Securities Litigation Reform Act. Examples of such statement may include, but are not limited to statements regarding our commercialization and continued development of SKYTROFA and YORVIPATH, the US and European markets, as well as certain financial expectations, our pipeline candidates and our expectations with respect to their continued progress and potential commercialization, our strategic plans, our goals regarding our clinical pipeline, including the timing of clinical results, our ongoing and planned regulatory filings for expectations regarding the timing and the results of regulatory decisions and our exploration of market opportunities in therapeutic areas outside of endocrinology rare disease.

These statements are based on information that is available to us as of today. Actual results may differ and could differ -- actual results may differ and could differ materially from those in our forward-looking statements and should not place undue reliance on these statements. We assume no obligation to update these statements as circumstances change, except as required by law. For additional information concerning the factors that can cause actual results to differ materially, please see our forward-looking statements section in today's press release in the Risk Factors section of our most recent annual report on Form 20-F filed with the SEC on February 7th, 2024.